QuelFromage
05 Jan 2018
MMs must be short of shares Nearly all trades recently appear to be buys ... at some point the MMs will need to adjust the price to persuade sellers which could mean raising or dropping the price significantly.(Unless they have an overhang of stock from the past??).QF
QuelFromage
12 May 2017
Re: Target Price 208p ... From a previous broker report:►Risks: There is a risk with all drugs in development that they might fail clinicaltrials or not be approved by the regulators. However, Diurnal is unusually lowrisk because its products are formulation variants of well-established drugs.Moreover, the PUMA dossier has been accepted for assessment by the EMA.► Investment summary: Diurnal is focusing on diseases of the endocrine system.Infacort, a cortisol replacement therapy designed for children and babies, is thefirst product Diurnal will bring to the market. It will be followed by Chronocortfor adults. The cortisol replacement market is for conditions that need life-long treatments, and has a potential value of $3.5bn.
QuelFromage
12 May 2017
Target Price 208p ... Broker Forecast - Cantor Fitzgerald issues a broker note on Diurnal Group PlcStockMarketWire | Fri, 12th May 2017 - 09:40Cantor Fitzgerald today initiates coverage of Diurnal Group Plc (LON
NL) with a buy investment rating and price target of 208p.
triceratops
27 Jan 2017
1st post I've bought a small chunk of these, the company have made good progress since IPO and shares haven't really discounted that in my view. Plus I notice the directors have been buying so take that as a sign things are going well at least in the short term.Fully aware these are incredibly risky and could well fall to nil. So will keep the holding firmly in "punt" territory.Tops
